COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.

MLA

von Metzler, Ivana, et al. “COVID-19 in Multiple-Myeloma Patients: Cellular and Humoral Immunity against SARS-CoV-2 in a Short- and Long-Term View.” Journal of Molecular Medicine, vol. 100, no. 3, Mar. 2022, pp. 463–70. EBSCOhost, https://doi.org/10.1007/s00109-021-02114-x.

APA

von Metzler, I., Campe, J., Huenecke, S., Raab, M. S., Goldschmidt, H., Schubert, R., Rabenau, H. F., Ciesek, S., Serve, H., & Ullrich, E. (2022). COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view. Journal of Molecular Medicine, 100(3), 463–470. https://doi.org/10.1007/s00109-021-02114-x

Chicago

von Metzler, Ivana, Julia Campe, Sabine Huenecke, Marc S. Raab, Hartmut Goldschmidt, Ralf Schubert, Holger F. Rabenau, Sandra Ciesek, Hubert Serve, and Evelyn Ullrich. 2022. “COVID-19 in Multiple-Myeloma Patients: Cellular and Humoral Immunity against SARS-CoV-2 in a Short- and Long-Term View.” Journal of Molecular Medicine 100 (3): 463–70. doi:10.1007/s00109-021-02114-x.